Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS

Next Previous
Search
Trial Profile

A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivuxolimab (Primary) ; Utomilumab (Primary)
  • Indications Bladder cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer; Uterine cancer; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer

    • Most Recent Events

    • 06 Oct 2021 Interim results (n=52) assessing the dose-escalation portion of the first-in-human phase I study of ivuxolimab in patients with locally advanced or metastatic cancers and analysis of biomarker studies is presented in parallel to support the immunomodulatory effects of ivuxolimab, published in the Clinical Cancer Research.
    • 22 Dec 2020 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2020 Planned End Date changed from 30 Jun 2020 to 22 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top